



Universiteit  
Leiden  
The Netherlands

## Inspire or expire: a matter of life or death

Lemmen, M.A. van

### Citation

Lemmen, M. A. van. (2025, December 5). *Inspire or expire: a matter of life or death*. Retrieved from <https://hdl.handle.net/1887/4284621>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4284621>

**Note:** To cite this publication please use the final published version (if applicable).

# **INSPIRE OR EXPIRE A MATTER OF LIFE OR DEATH**

Maarten van Lemmen

Academic thesis, Leiden University, Leiden, The Netherlands

ISBN: 978-94-6522-707-8

Author: M.A. van Lemmen

Design by: M.A. van Lemmen

Printed by: Ridderprint

© 2025, Maarten A. van Lemmen, Leiden, the Netherlands

All rights reserved. No part of this thesis may be reproduced, stored or transmitted in any form or by any means, without the author's permission.

Inspire or expire - a matter of life or death

Proefschrift

ter verkrijging van

de graad van doctor aan de Universiteit Leiden,

op gezag van rector magnificus prof.dr.ir. H. Bijl,

volgens besluit van het college voor promoties

te verdedigen op vrijdag 5 december 2025

klokke 11:30 uur

door

Maarten Albertus van Lemmen

geboren te Amersfoort

in 1998

**Promotor**

prof.dr. A. Dahan

**Copromotores**

dr. M. van Velzen

dr. R.M. van der Schrier

**Leden Promotiecommissie**

dr. A.M.M. Kraaijvanger

prof.dr. M.L. Bouvy (Universiteit Utrecht)

prof.dr. J.P. Rathmell (Harvard Medical school)

prof.dr. E.Y. Sarton



# Table of contents

|                  |                                                                                                                                                         |           |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| <b>Chapter 1</b> | Introduction and thesis outline                                                                                                                         | 8         |
| <b>Part I</b>    | <b>Understanding and detecting opioid-induced respiratory depression</b>                                                                                | <b>16</b> |
| <b>Chapter 2</b> | Principal component-based breath clustering for early recognition of severe opioid-induced respiratory depression – a pilot study                       | 18        |
| <b>Chapter 3</b> | Fentanyl-induced ventilatory depression: population pharmacokinetic-pharmacodynamic framework for evaluation of opioid-induced ventilatory depression   | 38        |
| <b>Part II</b>   | <b>Naloxone</b>                                                                                                                                         | <b>64</b> |
| <b>Chapter 4</b> | Opioid overdose: limitations in naloxone reversal of respiratory depression and prevention of cardiac arrest                                            | 66        |
| Chapter 4.1      | Naloxone for Opioid Overdose: comment                                                                                                                   | 86        |
| Chapter 4.2      | Naloxone for Opioid Overdose: comment                                                                                                                   | 90        |
| Chapter 4.3      | Naloxone for Opioid Overdose: reply                                                                                                                     | 94        |
| <b>Chapter 5</b> | A comparison of intramuscular (Zimhi) and intranasal naloxone (Narcan) in reversal of fentanyl-induced apnea: a randomized, crossover, open-label trial | 100       |

|                  |                                                                                                                                        |     |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------|-----|
| <b>Chapter 6</b> | Intranasal naloxone reversal of opioid-induced respiratory depression in opioid-naïve individuals and self-reported daily opioid users | 124 |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------|-----|

|                 |                               |            |
|-----------------|-------------------------------|------------|
| <b>Part III</b> | <b>Respiratory stimulants</b> | <b>146</b> |
|-----------------|-------------------------------|------------|

|                  |                                                                                                                                    |     |
|------------------|------------------------------------------------------------------------------------------------------------------------------------|-----|
| <b>Chapter 7</b> | Pharmacology of viable mechanism agnostic respiratory stimulants for the reversal of drug-induced respiratory depression in humans | 148 |
|------------------|------------------------------------------------------------------------------------------------------------------------------------|-----|

|                  |                                                                                                                                                                     |     |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| <b>Chapter 8</b> | TAK-925 (danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-Induced Respiratory Depression and Sedation Without Affecting Analgesia in Healthy Adult Males | 170 |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|

|                |                                        |            |
|----------------|----------------------------------------|------------|
| <b>Part IV</b> | <b>Summary and future perspectives</b> | <b>192</b> |
|----------------|----------------------------------------|------------|

|                  |                                              |     |
|------------------|----------------------------------------------|-----|
| <b>Chapter 9</b> | Summary, future perspectives and conclusions | 194 |
|------------------|----------------------------------------------|-----|

|               |                   |            |
|---------------|-------------------|------------|
| <b>Part V</b> | <b>Appendices</b> | <b>204</b> |
|---------------|-------------------|------------|

|                                 |            |
|---------------------------------|------------|
| <b>Nederlandse samenvatting</b> | <b>208</b> |
|---------------------------------|------------|

|                         |            |
|-------------------------|------------|
| <b>Curriculum vitae</b> | <b>215</b> |
|-------------------------|------------|

|                             |            |
|-----------------------------|------------|
| <b>List of publications</b> | <b>216</b> |
|-----------------------------|------------|

|                  |            |
|------------------|------------|
| <b>Dankwoord</b> | <b>218</b> |
|------------------|------------|